All companies
Visit website
PRESERVE
OperatingRecycline, Inc.
Industrial
Everyday products for a better world
Post-money valuation ⓘ
$29.7M
As of Jun 2023 · from Preserve Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$112,754
Across 1 round since 2023
Latest share price
$8.18
Preserve Common Stock 1 offering price
Financials
FY2020–FY2024 · from SEC filings · hover any figure for its source$7.4M
−$323K
2020
$7.4M
−$323K
2021
$8.4M
−$315K
2022
$9.0M
−$459K
2023
$8.4M
−$404K
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
FY2022
FY2023
FY2024
Income statement
Revenue
$7,402,355
$7,402,355
$8,415,980
$8,968,078
$8,366,682
Cost of goods sold
$5,347,230
$5,347,230
$6,217,501
$6,442,659
$5,943,356
Gross margin
28%
28%
26%
28%
29%
Net income
-$323,499
-$323,499
-$315,450
-$459,083
-$403,565
Taxes paid
$0
$0
$5,956
$3,042
$2,433
Balance sheet
Cash
$71,895
$71,895
$76,711
$93,530
$48,332
Accounts receivable
$610,165
$610,164
$582,635
$1,015,366
$451,677
Total assets
$4,356,686
$4,356,686
$3,887,497
$3,848,767
$2,782,749
Short-term debt
$1,773,183
$1,773,183
$236,960
$1,905,449
$1,868,883
Long-term debt
$4,290,571
$4,290,569
$4,096,896
$2,465,632
$2,327,430
Total liabilities
$6,063,754
$6,063,752
$4,333,856
$4,371,081
$4,196,313
Other
Headcount
—
5
5
9
8
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$29.7M
post-money
Preserve Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $112.8K / $1.2MInvestors 241Post-money $29.7M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 3 of 4 annual reports (FY2022–FY2025)
241 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001292625Share price $8.18
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.